Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) EBITDA (2016 - 2025)

Historic EBITDA for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$6.1 million.

  • Angiodynamics' EBITDA rose 4479.0% to -$6.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$32.5 million, marking a year-over-year increase of 8635.73%. This contributed to the annual value of -$40.0 million for FY2025, which is 7923.77% up from last year.
  • Per Angiodynamics' latest filing, its EBITDA stood at -$6.1 million for Q4 2025, which was up 4479.0% from -$10.7 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' EBITDA ranged from a high of $35.0 million in Q3 2023 and a low of -$199.9 million during Q1 2024
  • Moreover, its 5-year median value for EBITDA was -$9.5 million (2023), whereas its average is -$17.7 million.
  • In the last 5 years, Angiodynamics' EBITDA skyrocketed by 36336.37% in 2023 and then crashed by 213897.85% in 2024.
  • Over the past 5 years, Angiodynamics' EBITDA (Quarter) stood at -$8.7 million in 2021, then grew by 6.5% to -$8.1 million in 2022, then crashed by 61.68% to -$13.1 million in 2023, then rose by 15.44% to -$11.1 million in 2024, then soared by 44.79% to -$6.1 million in 2025.
  • Its EBITDA was -$6.1 million in Q4 2025, compared to -$10.7 million in Q3 2025 and -$5.8 million in Q2 2025.